OVERVIEW

This program will review the current state-of-the-art for breast cancer management, highlighting the key components of multi-disciplinary treatment to include breast imaging, oncofertility, breast pathology, surgical oncology, reconstructive microsurgery, medical oncology, and radiation oncology. The format of this program will consist of lectures by international experts in their fields.
Over the past year, advances in clinical trials have demonstrated the utility of antibody-drug conjugates, immunotherapy, genomic assays in hormone receptor-positive breast cancer, and downstaging surgical management of the axilla. The evolution of reconstructive microsurgery in oncoplastic and lymphedema surgery proceeds at a rapid pace. These developments, along with data on resistance to endocrine therapy and therapy targeting the HER2 axis, make individualized management decisions increasingly important in treating patients with breast cancer. Newer radiation therapy treatment strategies and clinical trials in radiation oncology continue to evolve.  Evolving technology in breast imaging, specifically tomosynthesis, is challenging conventional imaging techniques. Breast cancer in young women has become a specialized field in oncology, which is seeing increasing visibility. Inflammatory cancer continues to be a challenging area where new therapeutic concepts are emerging. These breakthroughs allow personalized breast cancer treatments to maximize benefits and minimize treatment toxicities.
The understanding of the HER2 receptor continues to evolve. Key talks in medical oncology will focus on HER2+ breast cancer therapeutics in the metastatic setting, the use of newer agents in metastatic ER+ cancers, and the evolution of immunotherapy as a central theme in the treatment of triple-negative breast cancer.

LEARNING OBJECTIVES

1. Understand the prognostic value of residual cancer remaining after neoadjuvant chemotherapy.
2. Identify the unique features of the I-SPY2 adaptive trial design.
3. Review the decision-making process in surgical management of the axilla.
4. Outline evolving concepts in treatment of inflammatory breast cancer.
5. Discuss outcomes after surgical management of lymphedema.
6. Explain the biology of the HER2 axis and its role in treating metastatic cancer.
7. State the role of newer agents in treating metastatic ER+ cancers.
8. Review newer concepts in treatment of triple negative breast cancers, including immunotherapy.
9. Integrate the evolving role of clinical trials in radiation therapy.
10. Describe the evolving expertise in treatment of young women with breast cancer.
11. Discuss the use of genomic assays in node-positive patients.
12. Assess the impact of advances in breast imaging.
13. Explain the importance of fertility preservation during breast cancer treatment.

ACCREDITATION

The Keck School of Medicine of the University of Southern California is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Keck School of Medicine of the University of Southern California designates this Live Activity activity for a maximum of 7.75 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.